Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
Executive Summary
With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.
You may also be interested in...
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.
‘Non-Medical Switching’ Claim Riles Europe’s Biosimilars Industry
Two patient advocacy groups have said that a number of issues surrounding biosimilar switching, patient consent and traceability remain to be addressed in Europe, despite growing support for biosimilar use from physician bodies and clinical studies. But the European biosimilars industry has dismissed these concerns, saying that biosimilar medicines will significantly improve access to biologics patients while contributing to the sustainability of pharmaceutical budgets.